Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.

Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM; Sitagliptin Study 024 Group..

Int J Clin Pract. 2010 Apr;64(5):562-76. doi: 10.1111/j.1742-1241.2010.02353.x.

PMID:
20456211
2.

Sitagliptin: a novel drug for the treatment of type 2 diabetes.

Choy M, Lam S.

Cardiol Rev. 2007 Sep-Oct;15(5):264-71. Review.

PMID:
17700385
3.

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.

Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP.

Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . Review.

PMID:
18182122
4.

New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

Gagliardino JJ, Santoro S, Arellano S, Di Girolamo G.

Expert Opin Pharmacother. 2008 Jun;9(9):1495-507. doi: 10.1517/14656566.9.9.1495 . Review.

PMID:
18518780
5.

Sitagliptin.

Lyseng-Williamson KA.

Drugs. 2007;67(4):587-97. Review.

PMID:
17352516
6.

Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.

Cornell S.

Postgrad Med. 2015 Apr;127(3):277-81. doi: 10.1080/00325481.2015.1018798. Review.

PMID:
25724655
7.

Metformin use among individuals at risk for type 2 diabetes.

Kuller LH.

Curr Diab Rep. 2012 Jun;12(3):265-73. doi: 10.1007/s11892-012-0263-x. Review.

PMID:
22399368
8.

Early insulin treatment in type 2 diabetes: what are the pros?

Meneghini LF.

Diabetes Care. 2009 Nov;32 Suppl 2:S266-9. doi: 10.2337/dc09-S320. Review. No abstract available.

9.

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.

Vuylsteke V, Chastain LM, Maggu GA, Brown C.

Drugs R D. 2015 Sep;15(3):227-32. doi: 10.1007/s40268-015-0099-3. Review.

10.

HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?

Reaven GM.

Diab Vasc Dis Res. 2009 Apr;6(2):133-8. doi: 10.1177/1479164109336038. Review. No abstract available.

PMID:
20368203
11.

Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?

Heine RJ, Diamant M, Mbanya JC, Nathan DM.

BMJ. 2006 Dec 9;333(7580):1200-4. Review. No abstract available.

12.

A new anti-asthmatic drug (ICI 58 301): blood levels and spirometry.

Richards AJ, Walker SR, Paterson JW.

Br J Dis Chest. 1971 Oct;65(4):247-52. Review. No abstract available.

PMID:
4332774

Supplemental Content

Support Center